KLRB1 and glioma: They set up in vitro co-cultures of HLA-A*02.01+ patient-derived gliomas and cell lines expressing the tumor antigen peptide NY-ESO-1, with engineered T cells that express a NY-ESO-1 specific HLA-A*02.01-restricted TCR, and either expressed or lacked CD161, deleted using a CRISPR-Cas9 approach.